Trial · NCT06986811
CEB-01 in Pediatrics With Locally Resectable Abdominal Tumors
NCT06986811, Phase 2, Active not recruiting, CEBIOTEX
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CEB-01 in Pediatrics With Locally Resectable Abdominal Tumors. Trials, record NCT06986811. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06986811
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CEB-01 in Pediatrics With Locally Resectable Abdominal Tumors
- NCT number
- NCT06986811
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- CEBIOTEX
- Conditions
- Locally Resectable Pediatrics Tumors
- Interventions
- Standard surgery, CEB-01
- First posted
- 2025-05-23
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency of Adverse Events (AEs) (Safety) | Through study completion, average 3 years | Adverse Events (AE), serious and non-serious, with their frequency, severity, and relatedness to study drug and coded according to the most updated version of the Common Terminology Criteria for Adverse Events (CTCAE). |
| Secondary | Progression-free survival (PFS) | Through study completion, average 3 years | Defined as the time from surgery to objective tumor progression or death from any cause. |
| Secondary | Overall survival (OS). | Through study completion, average 3 years | Defined as time from surgery to death from any cause. |
| Secondary | Local recurrence-free survival (LRFS) | Through study completion, average 3 years | Defined as the time from surgery until the progression of the disease in the area of implanted CEB-01. |
| Secondary | New lesions either distant or metastatic by RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1) | Through study completion, average 3 years | Number of new lesions either distant or metastatic by RECIST 1.1. (Response Evaluation Criteria in Solid Tumors, version 1.1) |
| Secondary | Area under the concentration-time curve (AUC0-inf) of SN-38 ( 7-ethyl-10-hydroxy Camptothecin) | During 60 days | Represents the total SN-38 (f 7-ethyl-10-hydroxy Camptothecin) exposure in the peripheral blood across time |
| Secondary | Maximum concentration (Cmax) of SN-38. | During 60 days | The highest concentration of SN-38 in the peripheral blood samples taken at sequential timepoints |
| Secondary | Time of maximum plasma concentration (Tmax) of SN38. | During 60 days | Time from the surgery to the moment with the highest concentration of SN-38 in the peripheral blood samples taken at sequential timepoints |
| Secondary | Terminal half-life (t1/2) of SN-38 | During 60 days | The time required for the plasma concentration of SN-38 to fall by 50% from the Cmax |
| Secondary | Score of Quality of Life | Through study completion, average 3 years | Quality of Life Questionnaire (QoL) using KIDSCREEN-27 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06986811
GET https://conductscience.org/api/trials/v1/NCT06986811/registered